Compare BJDX & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BJDX | AEMD |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | 2021 | 2008 |
| Metric | BJDX | AEMD |
|---|---|---|
| Price | $1.13 | $0.71 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 403.8K | 242.0K |
| Earning Date | 05-12-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $249,040.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $0.51 |
| 52 Week High | $7.00 | $5.89 |
| Indicator | BJDX | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 29.05 | 21.47 |
| Support Level | $0.63 | $0.51 |
| Resistance Level | $2.02 | $0.82 |
| Average True Range (ATR) | 0.56 | 0.17 |
| MACD | -0.45 | -0.10 |
| Stochastic Oscillator | 2.56 | 4.06 |
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.